Elsevier Business Intelligence announces the publication of a new Special Report: Medical Device Market 2009 Interventional Cardiology. Who’s going beyond catheters and drug-eluting stents in this vibrant space. A special report previously published in IN VIVO: The Business & Medicine Report™ Read more...
Sometime it seems as if there's so much activity in a therapeutic space, it's too much to absorb all at once. It may seem like only yesterday that bare-metal stents were the big blockbuster, and then came drug-eluting stents; will percutaneous valves be next? The devices that fill this space are numerous and diverse, and the most successful strategies so complex, that executives could spend years chasing the wrong idea and cost their companies millions.
Now this Special Report identifies the most important trends in cardiology devices in recent years, teases out the critical decisions that drove those developments, and takes you behind the scenes and into the minds of the architects of these new technologies and business strategies.
This detailed 86-page report includes critical information for business development, R&D, and product development and finance executives, and investors interested in the medical device cardiology industry.
Prepared by Elsevier Business Intelligence’s expert analysts, this Special Report reveals ...
** How a niche cardiac market company, reliant upon a Big Device company for its financing, reinvented itself after that partner changed its mind
** What happened when an innovative new product, despite FDA approval, wasn't ready for prime time with the doctors it's supposed to serve — and the clock was ticking on revenues
** How a combination of two technologies — one diagnostic and the other therapeutic — is driving a whole new class of device
** How one company is moving from simply selling blood marrow products into developing a system that will allow surgeons to treat cardiovascular disease with stem cells
How to build an infrastructure for an independent company after being someone else's division for years
… and much more
Steering through economic hard times
A device company whose share price actually rose in 2008 illustrates how you can start over even when your hot new technology fails to reach its commercial potential. Volcano has perfected the art of combining internal R&D flexibility with external acquisitions to achieve profitability, even while pioneering in entirely new technologies.
Secrets of success from a cardiology device legend
In this interview, device entrepreneur Fred Khosravi — one of the pioneers of the coronary stent revolution at Guidant — reveals his secrets for success in medical device company creation, from his first decision to accept a job offer out of college to his recent successful move into the closure field, despite protests from his colleagues: "Fred, are you crazy?"
When innovative R&D just isn't enough
The CEO of a company whose R&D has always been its strong point in establishing its Asian and European market share, but which had never really penetrated the U.S. market, reveals frankly how the company managed to bring its sales and marketing efforts up to the high level of its technology development.
These are just some of the issues and actionable guidance included in this report. And it could only be delivered by Elsevier Business Intelligence, provider of the most in-depth, accurate, expert business intelligence in health care today. Learn more...
Comments